Table 2.

Outcomes of patients with severe acute respiratory distress syndrome with COVID‐19 who were initiated on venovenous ECMO.

Survival to discharge, n (%)	26/41 (63.4)
Inpatient mortality, n (%)	15/41 (36.6)
Median duration of ECMO, days (IQR)	19 (13−30)
Median duration of ventilation, days (IQR)	33 (16−41)
Median length of stay of survivors, days (IQR)	37 (25−50.5)
Required tracheostomy, n (%)	19/41 (46)
Required reconfiguration of ECMO, n (%)	7/41 (17)
Extubated while on ECMO, n (%)	12/41 (29.2)
Complications
Blood stream infection, n (%)	7/41 (17.1)
Renal replacement therapy, n (%)	22/41 (53.7)
Bleeding, n (%)	18/41 (43.9)
Hemorrhagic brain injury, n (%)	2/41 (4.8)
Switched from heparin to argatroban	11/41 (26.9)

Abbreviations: ECMO, extracorporeal membrane oxygenation; IQR, interquartile range.